Cognition Therapeutics appoints John Doyle as CFO effective May 1, 2023

COGNITION THERAPEUTICS INC

John Doyle appointed CFO effective May 1; succeeds interim CFO Andrew Einhorn, who serves until May 15.
Base salary $415k, target bonus 40%, signing bonus $40k; equity grants: 109,824 options and 109,824 RSUs vesting over 4 years.
Prior roles include CFO of 4D Pharma and Chiasma, VP Finance at Verastem Oncology.
Severance: 9 months base salary on termination without cause; 12 months on change in control plus accelerated equity vesting.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed (interim)

Andrew Einhorn

Interim Chief Financial Officer

CGTX · COGNITION THERAPEUTICS INC

Effective: 2023-05-15
Successor: John Doyle
Filed: May 1, 2023, 7:59 PM ET

Mr. Doyle will succeed Mr. Andrew Einhorn, who has served as the Company’s Interim Chief Financial Officer since August 2022.

Appointed

John Doyle

Chief Financial Officer

CGTX · COGNITION THERAPEUTICS INC

Effective: 2023-05-01
Filed: May 1, 2023, 7:59 PM ET

On May 1, 2023, Cognition Therapeutics, Inc. (the “ Company ”) announced the appointment of John Doyle as Chief Financial Officer of the Company, effective May 1, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Andrew Einhorn departed as Interim Chief Financial Officer at COGNITION THERAPEUTICS INC.

Action: departing
Role: Interim Chief Financial Officer

Exact text from the filing

Mr. Doyle will succeed Mr. Andrew Einhorn, who has served as the Company’s Interim Chief Financial Officer since August 2022.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

John Doyle was appointed as Chief Financial Officer at COGNITION THERAPEUTICS INC.

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On May 1, 2023, Cognition Therapeutics, Inc. (the “ Company ”) announced the appointment of John Doyle as Chief Financial Officer of the Company, effective May 1, 2023.

View on SEC.gov

COGNITION THERAPEUTICS INC filing history →

Source: SEC EDGAR

accession 0001104659-23-053502

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.